FDA Approves Tivozanib for R/R Advanced RCC

On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved tivozanib for adult patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Read the FDA announcement.

Read AVEO Oncology's announcement.

Posted 3/11/2021